More healthy years

Aging populations will spend more on health technology.

By Sam Rivera

What’s inside

• ABT Abbott: Diagnostics plus cardiac and glucose devices aimed squarely at older patients
• MDT Medtronic: Pacemakers, pumps and spine hardware scale with the 65+ cohort
• BSX Boston Scientific: Cardiac rhythm and structural heart volumes grow with an aging patient pool
• SYK Stryker Corporation: Hip and knee replacement demand tracks the boomer wave directly
• ISRG Intuitive Surgical: Robotic surgery lifts throughput per surgeon as procedure demand outruns staffing
• DXCM Dexcom: Continuous monitoring moves chronic care out of the clinic and into the home
• LLY Eli Lilly: Obesity and diabetes drugs are the clearest commercial expression of age-related illness spend
• VRTX Vertex: Pipeline aimed at the chronic disease burden that rises with age
• TMO Thermo Fisher: Picks-and-shovels for longevity research and diagnostic scale-up
• DHR Danaher: Diagnostics and bioprocessing supply the testing boom behind healthspan claims
• XLV Health Care Select Sector SPDR: Keeps exposure to payers, facilities and pharma as aging spend spreads beyond devices

Why it could work

Aging populations will spend more on health technology. The basket combines direct participants and broader suppliers.

What could break it

Adoption could disappoint, competition could weaken margins, or high valuations could already price in the trend. Some holdings are broad, indirect proxies.

For learning only. Not investment advice.